Drug Profile

Research programme: cannabinoids/nA7ACHR agonists - 180 Life Sciences

Alternative Names: CBD therapies - 180 Life Sciences

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Katexco Pharmaceuticals
Developer 180 Life Sciences
Class Anti-inflammatories; Antigouts; Cannabinoids; Small molecules
Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Cannabinoid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Apr 2025 Preclinical development is ongoing for Ulcerative-colitis in United Kingdom (PO) (180 Life Sciences pipeline, April 2025)
28 Apr 2025 Discontinued - Preclinical for Gastrointestinal disorders in Canada (PO) before April 2025 (180 Life Sciences pipeline, April 2025)
28 Apr 2025 Discontinued - Preclinical for Gout in Canada (PO) before April 2025 (180 Life Sciences pipeline, April 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com